Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Short Interest Up 4,233.3% in October

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) saw a significant growth in short interest during the month of October. As of October 31st, there was short interest totalling 65,000 shares, a growth of 4,233.3% from the October 15th total of 1,500 shares. Approximately 4.6% of the shares of the company are sold short. Based on an average daily volume of 351,700 shares, the days-to-cover ratio is currently 0.2 days.

Salarius Pharmaceuticals Stock Performance

Shares of NASDAQ SLRX traded down $0.01 during trading hours on Thursday, reaching $1.40. 5,504 shares of the stock were exchanged, compared to its average volume of 789,410. The stock’s fifty day simple moving average is $1.57 and its 200 day simple moving average is $2.38. Salarius Pharmaceuticals has a 52 week low of $1.26 and a 52 week high of $7.27. The firm has a market capitalization of $2.02 million, a price-to-earnings ratio of -0.11 and a beta of 0.93.

About Salarius Pharmaceuticals

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.